AN HUGE UPDATED REVIEW ON DYSLIPIDEMIA ETIOLOGY WITH VARIOUS APPROACHES FOR ITS TREATMENT

被引:0
作者
Bisht, Asha [1 ]
Madhav, Nv Satheesh [2 ]
Upadhyaya, Kumud [3 ]
机构
[1] DIT, Fac Pharm, Near Mussoorie Divers Rd,Makkawala, Dehra Dun 248009, Uttrakhand, India
[2] DIT, Fac Pharm, Dehradun Inst Technol, Dehra Dun 248009, Uttrakhand, India
[3] GIS, Dehra Dun 248009, Uttrakhand, India
来源
PHARMACOPHORE | 2012年 / 3卷 / 06期
关键词
Cardiovascular diseases; Dyslipidemias; Atherosclerosis; Coronary artery disease; Cerebral vascular diseases; Pharmacological interventions;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Cardiovascular diseases are becoming an increasing problem worldwide and hypercholesterolemia has been correlated for coronary heart diseases. Hyperlipidemia or dyslipidemia is a condition, where the lipids present in blood viz. LDL, VLDL, triglycerides; HDL etc loose their normal levels resulting in imbalance of their levels. Long term increased levels of LDL, VLDL, triglycerides & decreased level of HDL results in hazardous effects such as myocardial infarction, cerebral stroke etc leading cause of mortality. Cardiovascular diseases (CVDS) carry a major health burden affecting humans. More than 80% of the world population is suffering from heart problems and if not treated earliest can be a major cause of death. Dyslipidemia is a highly predictive risk factor atherosclerosis, coronary artery disease and cerebral vascular diseases and impose a great risk. Epidemiologic, angiographic and postmortem studies have documented a causal relationship between elevated serum cholesterol levels and the genesis of coronary heart disease. This article aims at reviewing the complete overview on dyslipidemia, its impact on the progression of cardiovascular diseases, its various forms, pharmacological interventions involved in its treatment and most recent investigations which are fruitful in the understanding of the disease and helpful to take preventive measures for cardiovascular diseases.
引用
收藏
页码:244 / 264
页数:21
相关论文
共 39 条
  • [1] Apolipoproteins as predictors of ischaemic stroke in patients with a previous transient ischaemic attack
    Bhatia, M.
    Howard, S. C.
    Clark, T. G.
    Neale, R.
    Qizilbash, N.
    Murphy, M. F. G.
    Rothwell, P. M.
    [J]. CEREBROVASCULAR DISEASES, 2006, 21 (5-6) : 323 - 328
  • [2] Hypercholesterolaemia and its management
    Bhatnagar, Deepak
    Soran, Handrean
    Durrington, Paul N.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2008, 337 (7668): : 503 - 508
  • [3] The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor
    Brown, MS
    Goldstein, JL
    [J]. CELL, 1997, 89 (03) : 331 - 340
  • [4] ACQUIRED HYPERLIPIDEMIA (SECONDARY DYSLIPOPROTEINEMIAS)
    CHAIT, A
    BRUNZELL, JD
    [J]. ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA, 1990, 19 (02) : 259 - 278
  • [5] Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
    Cleeman, JI
    Grundy, SM
    Becker, D
    Clark, LT
    Cooper, RS
    Denke, MA
    Howard, WJ
    Hunninghake, DB
    Illingworth, DR
    Luepker, RV
    McBride, P
    McKenney, JM
    Pasternak, RC
    Stone, NJ
    Van Horn, L
    Brewer, HB
    Ernst, ND
    Gordon, D
    Levy, D
    Rifkind, B
    Rossouw, JE
    Savage, P
    Haffner, SM
    Orloff, DG
    Proschan, MA
    Schwartz, JS
    Sempos, CT
    Shero, ST
    Murray, EZ
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19): : 2486 - 2497
  • [6] Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays
    Cohen, Meital
    Yossef, Rami
    Erez, Tamir
    Kugel, Aleksandra
    Welt, Michael
    Karpasas, Mark M.
    Bones, Jonathan
    Rudd, Pauline M.
    Taieb, Julien
    Boissin, Herve
    Harats, Dror
    Noy, Karin
    Tekoah, Yoram
    Lichtenstein, Rachel G.
    Rubin, Eitan
    Porgador, Angel
    [J]. PLOS ONE, 2011, 6 (01):
  • [7] Dyslipidaemia
    Durrington, P
    [J]. LANCET, 2003, 362 (9385) : 717 - 731
  • [8] Apolipoprotein E polymorphism and cardiovascular disease: A HuGE review
    Eichner, JE
    Dunn, ST
    Perveen, G
    Thompson, DM
    Stewart, KE
    Stroehla, BC
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 155 (06) : 487 - 495
  • [9] The impact of our genes: Consequences of the apolipoprotein E polymorphism in Alzheimer disease and multiple sclerosis
    Fazekas, Franz
    Enzinger, Christian
    Ropele, Stefan
    Schmidt, Helena
    Schmidt, Reinhold
    Strasser-Fuchs, Siegrid
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 2006, 245 (1-2) : 35 - 39
  • [10] A SYSTEM FOR PHENOTYPING HYPERLIPOPROTEINEMIA
    FREDRICK.DS
    LEES, RS
    [J]. CIRCULATION, 1965, 31 (03) : 321 - &